Icatibant (Firazyr): Bradykinin B2 Antagonist Research Profile

# Icatibant (Firazyr): Bradykinin B2 Antagonist Research Profile

> Research Use Only (RUO) Disclaimer: Research-grade icatibant is intended exclusively for laboratory and preclinical research purposes. This article is educational. Firazyr® (icatibant) is a prescription medication approved by the FDA for adult patients with hereditary angioedema — it should only be used under medical supervision as prescribed. Nothing in this article constitutes medical advice.

Icatibant (brand name Firazyr®) is a first-in-class, synthetic decapeptide that selectively and competitively antagonizes the bradykinin B2 receptor (B2R). FDA-approved in 2011 for the acute treatment of hereditary angioedema (HAE) in adults, icatibant occupies a unique position at the convergence of peptide chemistry, kinin biology, and rare disease pharmacology.

For researchers studying the kallikrein-kinin system, vascular permeability, inflammatory signaling, or contact activation pathways, icatibant represents an indispensable pharmacological tool with well-characterized receptor kinetics and an established clinical safety profile.

---

What Is Icatibant?

Icatibant is a selective competitive antagonist of the bradykinin B2 receptor — the primary receptor through which bradykinin mediates vasodilation, pain, and vascular permeability. Unlike C1-esterase inhibitor replacements that act upstream by restoring a missing protein, icatibant works directly at the effector level, blocking bradykinin from binding its target receptor.

Key identifiers:

• •Chemical name: Icatibant acetate (formerly HOE 140)
• •CAS number: 138614-30-9
• •Molecular formula: C₅₉H₈₉N₁₉O₁₃S · xCH₃COOH
• •FDA approval: August 25, 2011
• •Indication: Acute attacks of hereditary angioedema (HAE) in adults ≥18 years
• •Route: Subcutaneous injection, 30 mg single dose
• •Current manufacturer: Takeda Pharmaceuticals (acquired from Shire)

---

Molecular Structure: A Bradykinin Mimic Engineered for Antagonism

Icatibant's structure is one of its most pharmacologically instructive features. It is a 10-amino acid synthetic peptidomimetic designed by modifying the native bradykinin nonapeptide sequence to convert agonist activity into potent, selective antagonism.

Sequence

The amino acid sequence of icatibant is:

H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH

Bradykinin itself is: H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH (9 residues)

Five Non-Proteinogenic Substitutions

Five of icatibant's ten amino acids are non-natural (non-proteinogenic), each serving a precise pharmacological role:

These modifications collectively confer three critical properties: (1) high selectivity for B2R over B1R, (2) resistance to metabolic degradation by kinin-degrading metalloproteases and aminopeptidases, and (3) potent competitive antagonism without receptor activation.

The result is a molecule with Ki values of approximately 0.8 nM at the bradykinin B2 receptor — roughly 10-fold more potent than bradykinin itself as a receptor binder, but completely silent as an agonist.

---

Mechanism of Action: Blocking the Terminal Step in HAE Pathophysiology

To understand how icatibant works, it helps to trace the full pathophysiological cascade of hereditary angioedema.

The Kinin Cascade in HAE

HAE (Types I and II) is caused by mutations in the SERPING1 gene encoding C1-esterase inhibitor (C1-INH). C1-INH normally suppresses two key serine proteases:

1. Factor XIIa (activated Hageman factor) — initiates the contact activation pathway

2. Plasma kallikrein — cleaves high-molecular-weight kininogen (HMWK) to generate bradykinin

In C1-INH deficiency, plasma kallikrein is unregulated. This produces excess bradykinin, which binds the B2 receptor on vascular endothelium and triggers:

• •Vasodilation via nitric oxide (NO) and prostacyclin (PGI₂) release
• •Increased vascular permeability via endothelial retraction and gap formation
• •Fluid extravasation into tissues → angioedema

HAE attacks involve subcutaneous, submucosal, and mucosal sites. Laryngeal attacks are potentially fatal if the airway is compromised.

Icatibant's Intervention Point

Icatibant acts at the terminal effector step — blocking bradykinin from binding B2R on endothelial cells. By competing with bradykinin at its receptor, icatibant:

• •Prevents bradykinin-mediated increase in vascular permeability
• •Inhibits smooth muscle contraction driven by B2R signaling
• •Blocks downstream NO and prostacyclin release
• •Does not affect upstream bradykinin generation (which continues during an attack)

This mechanism is distinct from all other HAE therapies and makes icatibant particularly valuable for studying receptor-level kinin pharmacology independent of upstream protease activity.

---

Clinical Development: The FAST Trial Program

FDA approval of icatibant was based on three Phase III randomized controlled trials collectively known as the FAST (For Angioedema Subcutaneous Treatment) program.

FAST-1 Trial

• •Design: Double-blind, randomized, placebo-controlled, multicenter
• •Patients: 56 patients with acute HAE (cutaneous or abdominal attacks)
• •Dose: Icatibant 30 mg SC single dose vs. placebo
• •Primary endpoint: Median time to clinically significant symptom relief

Results: The icatibant group achieved relief in 2.5 hours vs. 4.6 hours with placebo (p = 0.14 — not statistically significant). Post-hoc analysis identified that early rescue medication use in the placebo arm likely confounded the primary endpoint, attenuating the observed difference.

FAST-2 Trial

• •Design: Double-blind, randomized, active-controlled, multicenter
• •Patients: 74 patients with acute HAE (cutaneous or abdominal attacks)
• •Comparator: Oral tranexamic acid 3 g/day × 2 days (then-standard care in Europe)

Results: Icatibant achieved symptom relief in 2.0 hours vs. 12.0 hours with tranexamic acid (p < 0.001 — statistically significant). This trial provided robust evidence of icatibant's superiority over non-specific antifibrinolytic therapy.

FAST-3 Trial

• •Design: Double-blind, randomized, placebo-controlled (with open-label arm for severe laryngeal attacks)
• •Objective: Confirm efficacy and safety across cutaneous, abdominal, and laryngeal HAE presentations

Results: FAST-3 met its primary endpoint, demonstrating statistically significant and clinically meaningful symptom relief with icatibant versus placebo. No icatibant-treated subject required rescue medication before achieving symptom relief. Adverse event rates were similar between groups (41% icatibant vs. 52% placebo), with injection site reactions being the most common icatibant-specific finding — universally mild to moderate and transient.

Open-Label Extensions

Open-label extension studies of FAST-1 and FAST-2 evaluated repeat dosing across multiple HAE attacks. These demonstrated that icatibant maintained consistent efficacy and tolerability with repeated use, supporting its role in patient-administered home therapy.

---

Laboratory Research Applications

Beyond its clinical role in HAE, icatibant is widely used as a pharmacological research tool to interrogate bradykinin B2 receptor biology in vitro and in vivo.

Bradykinin Receptor Characterization

Icatibant is the reference antagonist for distinguishing B1R vs. B2R-mediated effects in pharmacological assays. Its picomolar-to-nanomolar affinity and >10,000-fold selectivity for B2R over B1R make it ideal for:

• •Receptor binding competition studies
• •Autoradiography of B2R distribution in tissue sections
• •Schild plot analysis to characterize B2R pharmacology in isolated tissue preparations

Published IC₅₀ values:

• •Guinea pig ileum contractions: 11 nM
• •Rat pulmonary artery contractions: 5.4 nM
• •Rat uterus contractions: 4.9 nM
• •Intracellular calcium elevation: 1 nM
• •EDRF (NO) release: 10 nM

Vascular Permeability Assays

Icatibant is routinely used in in vitro vascular permeability models (e.g., transendothelial electrical resistance [TEER] assays, Miles assay variants) to:

• •Confirm that observed permeability changes are bradykinin/B2R-mediated
• •Establish pharmacological dose-response relationships
• •Screen novel B2R antagonists against icatibant as a positive control

Kinin System Pharmacology Studies

Researchers studying the contact activation pathway (Factor XII → kallikrein → bradykinin → B2R) use icatibant to:

• •Isolate the B2R-dependent component of inflammatory responses
• •Study reciprocal B1R/B2R regulation (B1R is upregulated by inflammation; B2R is constitutively expressed)
• •Model bradykinin's role in ACE inhibitor-induced angioedema (a distinct, non-HAE condition where icatibant has shown clinical benefit in case series)

COVID-19 and ARDS Research

Emerging research has identified bradykinin storm as a potential mechanism contributing to vascular inflammation and ARDS in severe COVID-19. Icatibant has been studied in investigational pilot trials as a potential adjunct therapy, with researchers using it to evaluate whether B2R blockade can attenuate pulmonary vascular permeability in cytokine storm contexts. While not an approved COVID-19 treatment, this research exemplifies how icatibant serves as a mechanistic probe beyond HAE.

---

Comparator Landscape: HAE Therapeutics

Icatibant occupies a distinct mechanistic niche within the HAE treatment armamentarium:

Mechanism Comparison

Key Differentiators

vs. C1-esterase inhibitors (Berinert, Cinryze):

C1-INH concentrates work upstream by replenishing the deficient regulatory protein, thereby suppressing excess kallikrein and bradykinin production. They require intravenous administration, which may be a barrier in some acute settings. Icatibant bypasses the entire upstream cascade and acts directly at the receptor — useful when the patient cannot receive IV therapy or when upstream inhibitor replacement is unavailable.

vs. Ecallantide (Kalbitor):

Both ecallantide and icatibant are subcutaneous. Ecallantide inhibits plasma kallikrein (upstream of bradykinin generation), while icatibant blocks bradykinin at its receptor. The critical practical distinction: ecallantide carries a black box warning for anaphylaxis and must be administered by a healthcare professional in a monitored setting. Icatibant, without this restriction, enables patient self-administration — a major quality-of-life advantage for HAE patients.

For research purposes: Each agent can serve as a mechanistic probe at a different point in the kinin cascade, allowing researchers to dissect pathway biology with pharmacological specificity.

---

Safety Profile and Pharmacokinetics

Pharmacokinetics

Following a single 30 mg subcutaneous dose in adults:

• •Tmax: ~0.75 hours (rapid absorption)
• •Cmax: ~974 ng/mL
• •Half-life: ~1–2 hours
• •Bioavailability: ~97% (high SC bioavailability)
• •Protein binding: ~44%
• •Metabolism: Primarily proteolytic (not hepatic CYP enzymes — no significant drug-drug interactions via CYP450)
• •Excretion: Predominantly renal as inactive metabolites

The short half-life reflects the peptide nature of icatibant, but the pharmacodynamic duration of B2R blockade is sufficient (typically 6–8 hours) to allow a single dose to resolve most HAE attacks.

Adverse Effects

In clinical trials, the most common adverse events included:

• •Injection site reactions (occurring in essentially all subjects, but universally mild-to-moderate and transient)
• •Headache
• •Dizziness
• •Nausea
• •Pyrexia
• •Elevated liver transaminases (rare)

Cardiac caution: The B2 receptor plays a cardioprotective role by mediating ischemic preconditioning effects of bradykinin. Because icatibant blocks B2R, a theoretical concern exists for patients with acute myocardial infarction or unstable angina. Firazyr's prescribing information includes a warning for patients with acute ischemic heart disease — patients with these conditions were excluded from pivotal trials.

No Significant Drug Interactions

Because icatibant is metabolized proteolytically rather than via CYP450 enzymes, clinically meaningful pharmacokinetic drug interactions are not anticipated. Co-administration with angiotensin-converting enzyme inhibitors is noted in the label, as both can affect bradykinin levels.

---

Regulatory and Market Context

Icatibant was approved in Europe by the EMA in 2008, preceding its FDA approval (August 25, 2011). Its development was pioneered by Hoechst (the "HOE 140" designation) and later advanced by Shire Pharmaceuticals. Following Takeda's acquisition of Shire in 2019, Firazyr is now marketed by Takeda globally.

Generic icatibant products have received FDA approval, offering more accessible pricing for patients. The compound is also available from multiple research peptide suppliers for in vitro pharmacological research, where it is sold for research use only.

---

Reconstitution and Laboratory Handling

Research-grade icatibant acetate is typically supplied as a lyophilized powder. For in vitro applications:

• •Reconstitute in sterile water or physiological saline for biological assays
• •Storage: Lyophilized product stable at -20°C; working solutions should be prepared fresh or stored at 4°C for short-term use
• •DMSO solubility: Icatibant has limited DMSO solubility; aqueous reconstitution is preferred for receptor binding studies
• •For detailed reconstitution guidance, see: How to Reconstitute Peptides

---

Summary

Icatibant (Firazyr) is a landmark compound at the intersection of peptide chemistry and rare disease pharmacology. Its 10-amino acid structure — engineered through five strategic non-natural substitutions — achieves potent, selective bradykinin B2 receptor antagonism with metabolic stability sufficient for subcutaneous administration. The FAST trial program established its clinical efficacy and favorable safety profile, leading to FDA approval in 2011.

For researchers, icatibant offers a well-validated pharmacological tool for dissecting bradykinin signaling, characterizing B1R/B2R biology, and modeling kinin-mediated vascular permeability in vitro. Its unique position as the only B2R-specific antagonist with a clinical approval record makes it an indispensable reference compound for the kinin pharmacology field.

---

Research Tools & Comparisons

Exploring icatibant for your research? Use these site tools:

• •Peptide Dosing Calculator — Calculate molar concentrations, reconstitution volumes, and working solution dilutions for icatibant and other research peptides.
• •Compare Peptide Suppliers — Side-by-side comparison of research-grade icatibant suppliers by purity specs, pricing, and certifications.

This article is for educational and research purposes only. Firazyr® (icatibant) is a prescription medication and should only be used under appropriate medical supervision. Research-grade icatibant is for laboratory use only and is not intended for human administration.

Sources:

• •Cicardi M et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. NEJM. 2010;363(6):532-541. PMID: 20818888
• •Lumry WR et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107(6):529-537.
• •Lefort J et al. Icatibant, the bradykinin B2 receptor antagonist with target to the interconnected kinin systems. Allergy. 2012;67:S-supplemental. PMID: 22970904
• •FDA drug approval announcement, August 2011